{
  "id": 6577498,
  "title": "BioLineRx, Hemispherian to present GLIX1 data at EANO meeting",
  "url": "https://urgent.news/2026/09/10/biolinerx-hemispherian-to-present-glix1-data-at-eano-meeting",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-10T11:04:36.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/biolinerx-hemispherian-to-present-glix1-data-at-eano-meeting-93CH-4895546"
  },
  "original_language": "en",
  "account": "Tel Aviv and Oslo - BioLineRx Ltd. and Hemispherian AS have announced that abstracts focusing on GLIX1 will be presented at the European Association of Neuro-Oncology's 21st Meeting in Rome, Italy. One of the presentations, featuring preclinical efficacy data of GLIX1 in glioblastoma models, will be an oral talk scheduled for Friday, September 25 at 6:00-6:30pm CEST. Dr. Adam Robertson, Hemispherian's Chief Scientific Officer, will discuss how GLIX1, an oral TET2 activator targeting the DNA damage response, achieved 68-85% of plasma levels in mice and demonstrated dose-dependent tumor growth inhibition and survival benefit in two glioblastoma models. The electronic poster will detail the ongoing Phase 1/2a clinical trial of GLIX1 in recurrent or progressive high-grade glioma, currently enrolling patients at four U.S. academic institutions.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}